Tavo Biotherapeutics Raises $17M Series A for Eye Disease

Fundraise Insider tracks newly funded startups each week and delivers verified C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Tavo Biotherapeutics, a biotech company based in the Dorchester area of Massachusetts, has closed a $17 million Series A financing. The round closed on June 2, 2026.

Pureos Bioventures led the round, with Polaris Partners joining in and continued support from existing investor Tau Capital. The company will use the proceeds to advance its pipeline of therapies targeting glaucoma and retinal disease.

Tavo is moving two primary programs forward. The first, TAV-001, is being studied as a potential disease-modifying topical therapy for glaucoma. It uses a dual mode of action that targets the autonomic nervous system, which drives the mechanisms behind inflammation and degeneration in glaucoma. That program is set to move into a Phase 2 clinical trial in the second half of 2026.

The second program, TAV-002, is a bispecific antibody that targets both VEGF and a protein involved in upstream signaling in serious retinal diseases. These include both wet and dry forms of age-related macular degeneration as well as diabetes-related retinopathies.

Alongside the financing, Tavo appointed Federico Grossi, M.D., Ph.D., as Chief Medical Officer to lead its clinical development strategy and execution. Daniel Bradbury also joined the Board of Directors as Chairman.